Skip to content

Vaxcyte

US · PCVX #1630 by market cap Listed 2020
55.39 -2.97 -5.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $125
    Market Newswire · 2026/10/20
  • BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
    Market Newswire · 2026/11/6
  • Rating change
    Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116
    Market Newswire · 2026/7/14
  • Rating change
    BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $133
    Market Newswire · 2026/8/6
  • Rating change
    A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $122 to $163
    Market Newswire · 2026/10/6
  • Rating change
    Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/9/25
  • TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/11/5
  • Rating change
    Cantor Fitzgerald Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $120
    Market Newswire · 2026/10/12
  • Rating change
    TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $75
    Market Newswire · 2026/2/25
  • Rating change
    Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $110
    Market Newswire · 2026/1/7
  • Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $125
    Market Newswire · 2026/10/5
  • Rating change
    Evercore Maintains Vaxcyte(PCVX.US) With Buy Rating
    Market Newswire · 2026/5/21
  • Rating change
    Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2025/12/9
  • Rating change
    Goldman Sachs Maintains Vaxcyte(PCVX.US) With Hold Rating, Raises Target Price to $85
    Market Newswire · 2026/10/7
  • BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $89
    Market Newswire · 2026/11/5
  • Rating change
    Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163
    Market Newswire · 2026/6/3
  • Rating change
    Goldman Sachs Maintains Vaxcyte(PCVX.US) With Hold Rating, Maintains Target Price $67
    Market Newswire · 2026/2/26
  • Rating change
    BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $85
    Market Newswire · 2026/2/13
  • Rating change
    A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $67 to $133
    Market Newswire · 2026/2/26
  • Rating change
    TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2025/11/5
  • Rating change
    BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $89
    Market Newswire · 2026/7/30
  • Rating change
    BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
    Market Newswire · 2026/9/28
  • Rating change
    TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/8/6
  • Vaxcyte: Offerings Expected to Close Oct. 9 PCVX
    Dow Jones · 2026/10/7
  • Rating change
    BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134
    Market Newswire · 2025/10/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vaxcyte discussion 0 comments

Add a comment